diseases, blood cell disorders, and various cancers.

Applications

- Adenovirus with gene plus
  Biotinylation kit with strepavidin with ligand or antibody for gene of interest
- Biotin linking kits with methods for use

Development Status: Delivery of the biotinylated recombinant adenoviral vector in vitro for use in targeted gene transfer.

Inventors: Jonathan Keller et al. (NCI).

Publications


Patent Status


Licensing Status: Available for licensing.

Licensing Contact: Whitney A. Hastings; 301–451–7337; hastingw@mail.nih.gov.


Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. E9–10300 Filed 5–4–09; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Center for Injury Prevention and Control, Initial Review Group, (NCIPC, IRG)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned review group:

Times and Date: 12:30 p.m.–1 p.m., May 20, 2009 (Open). 1 p.m.–5 p.m., May 20, 2009 (Closed).


Participant Passcode: 4424802.

Status: Portions of the meetings will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5, U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Section 10(d) of Public Law 92–463.

Purpose: This group is charged with providing advice and guidance to the Secretary, Department of Health and Human Services, and the Director, CDC, concerning the scientific and technical merit of grant and cooperative agreement applications received from academic institutions and other public and private profit and nonprofit organizations, including State and local government agencies, to conduct specific injury research that focuses on prevention and control.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of individual research cooperative agreement applications submitted in response to Fiscal Year 2009 Requests for Applications related to the following individual research announcement: RFA–EH–09–002 “Program to Expand State Public Health Laboratory Capacity for Newborn Bloodspot Screening (U01)”.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Jane Suen, Dr.P.H., M.S., NCIPC, CDC, 4770 Buford Highway, NE., Mailstop F–62, Atlanta, Georgia 30341. Telephone: (770) 488–4281.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: April 24, 2009.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E9–10292 Filed 5–4–09; 8:45 am]

BILLING CODE 4163–18–P